Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Novel human anticancer vaccine elicits cellular responses

May 12, 2004

Australian Pentrys phase II trial commences

May 5, 2004

Phase II TroVax trial cleared to commence for metastatic renal cancer

May 3, 2004

Positive data for HuMax-CD4 in phase II CTCL studies

April 30, 2004

Esteve takes marketing rights to Wilex's Rencarex in Southern Europe

April 30, 2004

Phase III results of R-1549 in ovarian cancer disappoint

April 28, 2004

Aastrom receives grant to develop immunotherapy for malignant melanoma

April 27, 2004

Phase II trial studies Xcellerated T Cells for multiple myeloma

April 20, 2004

Scottish government grant supports anti-CD55 antibody development at Viragen

April 20, 2004

Early completion of enrollment in pivotal Actimmune trial for ovarian cancer

April 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.